Arrowhead Research said this week that it has signed a deal under which an undisclosed Merck subsidiary will evaluate a novel therapeutic monoclonal antibody candidate developed through its human-derived peptide targeting and discovery program.
Merck will be responsible for the costs associated with the arrangement. Additional terms were not disclosed.
Arrowhead picked up the peptide technology through its April acquisition of Alvos Therapeutics (GSN 4/12/2012).